168 related articles for article (PubMed ID: 26571369)
21. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
22. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
[TBL] [Abstract][Full Text] [Related]
23. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
24. Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index.
Coscia EB; Sabha M; Gerenutti M; Groppo FC; Bergamaschi CC
Rev Bras Ginecol Obstet; 2017 Jan; 39(1):14-20. PubMed ID: 28187491
[No Abstract] [Full Text] [Related]
25. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
26. Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs).
Artac M; Bozcuk H; Kiyici A; Eren OO; Boruban MC; Ozdogan M
Breast Cancer; 2013 Apr; 20(2):174-80. PubMed ID: 22203581
[TBL] [Abstract][Full Text] [Related]
27. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
28. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle.
Wolters R; Schwentner L; Regierer A; Wischnewsky M; Kreienberg R; Wöckel A
Breast Cancer Res Treat; 2012 Feb; 131(3):925-31. PubMed ID: 22080246
[TBL] [Abstract][Full Text] [Related]
29. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
30. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis.
Dranka-Bojarowska D; Lekstan A; Olakowski M; Jablonska B; Lewinski A; Musialski P; Sobczyk W; Kapalka A; Lampe P
J Physiol Pharmacol; 2015 Oct; 66(5):653-63. PubMed ID: 26579571
[TBL] [Abstract][Full Text] [Related]
31. Leptin and adiponectin levels in pubertal children: relationship with anthropometric variables and body composition.
Schoppen S; Riestra P; García-Anguita A; López-Simón L; Cano B; de Oya I; de Oya M; Garcés C
Clin Chem Lab Med; 2010 May; 48(5):707-11. PubMed ID: 20450333
[TBL] [Abstract][Full Text] [Related]
32. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Lønning PE; Haynes BP; Dowsett M
Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
[TBL] [Abstract][Full Text] [Related]
33. Leptin, insulin and body composition changes during adjuvant taxane based chemotherapy in patients with breast cancer, preliminary study.
Alacacioglu A; Kebapcilar L; Gokgoz Z; Oztekin O; Bozkaya G; Tarhan O; Somali I; Yuksel A; Sop G; Sari I
Indian J Cancer; 2016; 53(1):39-42. PubMed ID: 27146736
[TBL] [Abstract][Full Text] [Related]
34. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
[TBL] [Abstract][Full Text] [Related]
35. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
36. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
37. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
van de Velde CJ; Verma S; van Nes JG; Masterman C; Pritchard KI
Cancer Treat Rev; 2010 Feb; 36(1):54-62. PubMed ID: 19944537
[TBL] [Abstract][Full Text] [Related]
38. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
39. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Buzdar AU; Cuzick J
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
[TBL] [Abstract][Full Text] [Related]
40. Effects of tamoxifen on the serum leptin level in patients with breast cancer.
Ozet A; Arpaci F; Yilmaz MI; Ayta H; Ozturk B; Komurcu S; Yavuz AA; Tezcan Y; Acikel C
Jpn J Clin Oncol; 2001 Sep; 31(9):424-7. PubMed ID: 11689595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]